PriceTargets.com logo

Dr. Martens - DOCS Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: GBX 177.50
  • Forecasted Upside: 154.12%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 69.85 As of 04/18/2024 06:07 PM ET
▲ +2.85 (4.25%)

This chart shows the closing price for DOCS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Dr. Martens Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DOCS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DOCS

Analyst Price Target is GBX 177.50
▲ +154.12% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Dr. Martens in the last 3 months. The average price target is GBX 177.50, with a high forecast of GBX 180 and a low forecast of GBX 175. The average price target represents a 154.12% upside from the last price of GBX 69.85.

This chart shows the closing price for DOCS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 polled investment analysts is to moderate buy stock in Dr. Martens. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/26/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/23/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/19/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
6/5/2023BarclaysReiterated RatingOverweightGBX 175
5/30/2023Royal Bank of CanadaDowngradeSector PerformGBX 230 ➝ GBX 180
2/24/2023Numis SecuritiesReiterated RatingAddGBX 180
11/18/2022JPMorgan Chase & Co.Reiterated RatingOutperformGBX 350
4/13/2022BarclaysLower TargetOverweightGBX 480 ➝ GBX 360
4/11/2022Royal Bank of CanadaReiterated RatingOutperformGBX 375
3/24/2022Royal Bank of CanadaReiterated RatingOutperformGBX 375
12/1/2021BarclaysUpgradeOverweightGBX 480
11/22/2021Royal Bank of CanadaReiterated RatingOutperformGBX 525
7/13/2021The Goldman Sachs GroupUpgradeBuyGBX 535
6/18/2021BarclaysReiterated RatingOverweight£125
3/11/2021Royal Bank of CanadaReiterated RatingOutperformGBX 550
(Data available from 4/18/2019 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023
  • 3 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2023
  • 0 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2023
  • 9 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Mentions as of
12/20/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/19/2024
  • 1 very positive mentions
  • 8 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
2/18/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/19/2024
  • 9 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 2 very negative mentions
Mentions as of
4/18/2024

Current Sentiment

  • 9 very positive mentions
  • 19 positive mentions
  • 5 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Dr. Martens logo
Dr. Martens plc designs, develops, procures, markets, sells, and distributes footwear in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. It offers originals, fusion, kids, and casual, as well as accessories. The company offers its products under the Dr. Martens brand name. Dr. Martens plc was founded in 1945 and is based in London, the United Kingdom.
Read More

Today's Range

Now: GBX 69.85
Low: 65.65
High: 71.15

50 Day Range

MA: GBX 90.93
Low: 67
High: 97.80

52 Week Range

Now: GBX 69.85
Low: 62
High: 174.70

Volume

5,986,472 shs

Average Volume

1,514,012 shs

Market Capitalization

£671.85 million

P/E Ratio

698.50

Dividend Yield

6.58%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Dr. Martens?

The following Wall Street sell-side analysts have issued research reports on Dr. Martens in the last twelve months: Barclays PLC, and Royal Bank of Canada.
View the latest analyst ratings for DOCS.

What is the current price target for Dr. Martens?

2 Wall Street analysts have set twelve-month price targets for Dr. Martens in the last year. Their average twelve-month price target is GBX 177.50, suggesting a possible upside of 154.1%. Royal Bank of Canada has the highest price target set, predicting DOCS will reach GBX 180 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of GBX 175 for Dr. Martens in the next year.
View the latest price targets for DOCS.

What is the current consensus analyst rating for Dr. Martens?

Dr. Martens currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for DOCS.

What other companies compete with Dr. Martens?

Other companies that are similar to Dr. Martens include McCarthy & Stone, Pendragon, PPHE Hotel Group, CVS Group and Pinewood Technologies Group. Learn More about companies similar to Dr. Martens.

How do I contact Dr. Martens' investor relations team?

Dr. Martens' physical mailing address is 28 Jamestown Road, Camden, London NW1 7BY, United Kingdom. The company's listed phone number is 44 12 1415 7047. The official website for Dr. Martens is www.drmartensplc.com. Learn More about contacing Dr. Martens investor relations.